Hydrocortisone Hemisuccinate: per day.

ApprovedSmall molecule

UUniversity Hospital, Strasbourg, France

Hydrocortisone Hemisuccinate: per day. is one of 17 small molecule programs targeting Acute Respiratory Failure. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Respiratory FailureActive, not recruiting

Acute Respiratory FailureApproved

Active, not recruiting

Competition

Competitive Landscape

28 competitors in Acute Respiratory Failure

#DrugCompanyPhaseTrials

Heparin Sodium

BBaxter Healthcare Corporation

Phase 3

2 2

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

1 3

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 4

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 5

Neupogen

EEastern Cooperative Oncology Group

Phase 3

1 6

Activase

Roche

Phase 2

1 7

Medrol

Pfizer

Phase 2

1 8

Aurlumyn

BBTG International Inc.

Phase 2

1 9

Hydrocortisone Hemisuccinate: per day.

UUniversity Hospital, Strasbourg, France

Approved

1 10

ABX464

AAbivax S.A.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Post-ApprovalNot yet recruiting

Acute Respiratory Failure

NCT06881927

Clinical

Trials by Indication[1]

Acute Respiratory Failure1 trial

Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure

Not yet recruiting·UUniversity Hospital, Strasbourg, France·Phase 4·NCT06881927·212 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Hydrocortisone Hemisuccinate: per day.. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hydrocortisone Hemisuccinate: per day. compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hydrocortisone Hemisuccinate: per day.. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Strasbourg, France company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity Hospital, Strasbourg, France

Hydrocortisone Hemisuccinate: per day.

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Acute Respiratory Failure1 trial

References

Drug Info

Quick Facts

Related News